Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

5 Nov 2013

Abstract excerpt

BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase 1 (PARP-1) and the balance between BRCA1 and 53BP1 play a key role in the DNA repair and cell stress response. PARP inhibitors show promising clinical activity in metastatic triple negative (TN) or BRCA-mutated breast cancer. However, a comprehensive analysis of PARP-1 activity, BRCA1 promoter methylation and 53BP1 expression in tumours without known BRCA1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24191908
DOI: 10.1186/1471-2407-13-523

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerPMID 24191908Read ↗

Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.Semantic proximity Read ↗

Biological and clinical significance of PARP1 protein expression in breast cancer.Semantic proximity Read ↗

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitorSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.Semantic proximity Read ↗

Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.Semantic proximity Read ↗

Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.Semantic proximity Read ↗

A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.Semantic proximity Read ↗

The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical DetectionSemantic proximity Read ↗

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Semantic proximity Read ↗

PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaSemantic proximity Read ↗

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.